Abstract
Background: The treatment of patients hospitalized with heart failure (HHF) and ambulatory chronic heart failure (CHF) differs in various countries. Objectives: To evaluate the management and outcomes of patients with HFF and CHF in Israel compared to those in other European countries who were included in the ESC-HF LongTerm Registry. Methods: From May 2011 to April 2013, heart failure patients – 467 Israelis and 11,973 from other countries – were evaluated. The Israeli patients comprised 178 with HHF and 289 with CHF. One year outcomes, including all-cause and cardiovascular mortality as well as HHF, were evaluated. Results: The HHF Israeli patients were older than their CHF Israeli counterparts, had more co-morbidities, included more women, and were treated less frequently with medications suggested by European guidelines. The Israeli HHF patients had similar all-cause 1 year mortality rates compared to HHF patients from other participating countries, but their cardiovascular (CV) mortality was lower, while a significantly higher rate of all-cause and HHF was noted. The Israeli CHF patients were older, suffered from more co-morbidities and had prior cardio-electronic implantable devices. In addition, they had higher mortality rates, especially non-CV, and were more frequently hospitalized, compared to CHF patients from other countries. Conclusions: The Israeli patients with heart failure differed in their baseline characteristics and the therapeutic approach. Despite high usage of treatments recommended by official guidelines, especially among CHF patients, mortality, particularly in HHF patients, remained high.
| Original language | English |
|---|---|
| Pages (from-to) | 225-230 |
| Number of pages | 6 |
| Journal | Israel Medical Association Journal |
| Volume | 19 |
| Issue number | 4 |
| State | Published - Apr 2017 |
Bibliographical note
Publisher Copyright:© 2017, Israel Medical Association. All rights reserved.
Funding
The survey in Israel was funded by the ESC, as is the case for each participating national cardiology society. Additional grant support was provided by Pfizer Israel and Astra Zenica Israel.
| Funders | Funder number |
|---|---|
| Pfizer Israel and Astra Zenica Israel | |
| European Society of Contraception and Reproductive Health |
Keywords
- Angiotensin-converting enzyme (ACE) inhibitors
- Beta-blockers
- Heart failure (HF)
- Mortality
- Rehospitalization